iHuman
iHuman's revenue fell 12.5% to CN¥807 million in fiscal 2025. Its operating margin was 8.3%, up from 7.8% a year earlier. Free cash flow was CN¥46 million, down 9.2%. It paid out CN¥56 million in dividends and buybacks, 121% of free cash flow. The diluted share count fell 1.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2022 to 2025, earnings per share fell 4.2% a year and net income 4.6% a year, while buybacks cut the share count by 1%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 855 | 1,050 | 1,214 | 1,169 | — |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 2.1x | 2.2x | 2.8x | 3.0x | 3.6x |
| Quick ratio | 2.0x | 2.2x | 2.8x | 2.9x | 3.5x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 19.6% | −3.9% | −6.7% |
| Altman Z'' | 6.50 | 6.55 | 7.73 |
| Accruals ratio | 0.6% | 2.8% | 3.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Pass | Pass |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put iHuman side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| iHuman | FY25 | −12.5% | 8.3% | 5.8% | — | — | — | |
| Universal Technical Institute | FY25 | 14.1% | 10.0% | 6.6% | 24.0% | −0.3x | 6 | Compare |
| Perdoceo Education | FY25 | 24.2% | 23.2% | 25.6% | — | — | — | Compare |
| Coursera | FY25 | 9.0% | −10.2% | 14.2% | — | — | 5 | Compare |
| American Public Education | FY25 | 3.9% | 7.4% | 7.1% | 14.4% | −1.2x | 7 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 132 | 219 | 532 | 945 | 986 | 1,018 | 922 | 807 |
| Revenue growth | — | 65.8% | 143.3% | 77.6% | 4.3% | 3.3% | −9.4% | −12.5% |
| Gross profit | 66 | 134 | 365 | 661 | 691 | 721 | 640 | 548 |
| Research and development | 52 | 170 | 200 | 415 | 314 | 258 | 248 | 208 |
| Operating income | −22 | −279 | −44 | −54 | 112 | 160 | 72 | 67 |
| Net income | −18 | −276 | −38 | −37 | 110 | 181 | 99 | 95 |
| Diluted EPS (CNY) | −0.11 | −1.52 | −0.21 | −0.14 | 0.41 | 0.66 | 0.36 | 0.36 |
| Diluted shares (millions) | 160 | 181 | 226 | 267 | 270 | 274 | 271 | 268 |
| Cash flow | ||||||||
| Cash from operations | −4 | 43 | 223 | 38 | 188 | 172 | 58 | 51 |
| Capital expenditure | 0 | 2 | 16 | 32 | 7 | 6 | 7 | 5 |
| Free cash flow | −5 | 40 | 207 | 6 | 182 | 166 | 51 | 46 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 39 |
| Share buybacks | 0 | 0 | 0 | 0 | 7 | 10 | 10 | 17 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 270 | 80 | 15 | 13 | 9 | 3 | 1 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 6 | 105 | 862 | 855 | 1,050 | 1,214 | 1,169 | — |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | — | 168 | 1,047 | 1,101 | 1,333 | 1,450 | 1,420 | 1,368 |
| Total liabilities | — | 183 | 404 | 492 | 564 | 493 | 459 | 373 |
| Shareholders' equity | −64 | −135 | 643 | 608 | 770 | 958 | 961 | 995 |
| Margins and ratios | ||||||||
| Gross margin | 50.1% | 61.5% | 68.7% | 69.9% | 70.1% | 70.8% | 69.4% | 67.9% |
| Operating margin | −16.7% | −127.5% | −8.4% | −5.7% | 11.3% | 15.7% | 7.8% | 8.3% |
| Net margin | −13.3% | −126.0% | −7.0% | −3.9% | 11.1% | 17.8% | 10.7% | 11.8% |
| Free cash flow margin | −3.8% | 18.4% | 38.9% | 0.6% | 18.5% | 16.3% | 5.5% | 5.8% |
| Rule of 40 (growth + FCF margin) | — | 84.2% | 182.2% | 78.2% | 22.8% | 19.6% | −3.9% | −6.7% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −14.8% | −5.9% | 15.9% | 20.9% | 10.3% | 9.8% |
| Return on assets | — | — | −6.2% | −3.5% | 9.0% | 13.0% | 6.9% | 6.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |